BRIDGEWATER, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go Wearable Insulin Delivery device, announced today it expects to report revenue of approximately $6.4 million for the first quarter ended March 31, 2019. In addition, Valeritas does not expect any significant changes from its first quarter 2019 guidance that it released on March 5, 2019, as the Company will achieve all metrics it provided guidance on for the quarter. Valeritas intends to report its full first quarter 2019 financial results on May 9, 2019.

Commenting on the announcement, John Timberlake, President and CEO of Valeritas stated, “I am very pleased with the first quarter results and all signs currently indicate this momentum should continue throughout 2019.”

The Company is announcing its first quarter revenue estimate due to investor meetings taking place today, May 2, 2019.

About Valeritas Holdings, Inc.

Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go^® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with type 2 diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots. V-Go administers a continuous preset basal rate of insulin over 24 hours, and it provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.

More information is available at www.valeritas.com and our Twitter feed @Valeritas_US, www.twitter.com/Valeritas_US.